Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Comerica Bank

Comerica Bank trimmed its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 25.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,805 shares of the company’s stock after selling 4,101 shares during the quarter. Comerica Bank’s holdings in Amphastar Pharmaceuticals were worth $438,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its stake in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after buying an additional 1,347,775 shares in the last quarter. D.A. Davidson & CO. purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $417,000. Barclays PLC boosted its position in Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company’s stock valued at $3,613,000 after buying an additional 25,878 shares during the period. Polaris Capital Management LLC purchased a new position in Amphastar Pharmaceuticals in the 4th quarter valued at approximately $910,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth $3,450,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Trading Up 4.4%

AMPH stock opened at $24.32 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The business has a fifty day simple moving average of $25.48 and a 200-day simple moving average of $34.14. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 8.11, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 5,231 shares of company stock valued at $142,752 in the last ninety days. Insiders own 27.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.